1. Home
  2. TVTX vs MC Comparison

TVTX vs MC Comparison

Compare TVTX & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$56.17

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Logo Moelis & Company

MC

Moelis & Company

HOLD

Current Price

$68.24

Market Cap

4.9B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
MC
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.9B
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
TVTX
MC
Price
$56.17
$68.24
Analyst Decision
Strong Buy
Buy
Analyst Count
13
8
Target Price
$40.62
$72.88
AVG Volume (30 Days)
1.8M
891.6K
Earning Date
05-04-2026
04-29-2026
Dividend Yield
N/A
3.88%
EPS Growth
92.89
N/A
EPS
N/A
0.75
Revenue
N/A
N/A
Revenue This Year
$44.76
$18.28
Revenue Next Year
$35.51
$17.22
P/E Ratio
N/A
$89.39
Revenue Growth
N/A
N/A
52 Week Low
$15.03
$51.06
52 Week High
$60.10
$78.22

Technical Indicators

Market Signals
Indicator
TVTX
MC
Relative Strength Index (RSI) 55.14 53.13
Support Level $54.87 $68.19
Resistance Level $59.89 $72.13
Average True Range (ATR) 2.37 2.55
MACD -0.66 0.16
Stochastic Oscillator 46.64 57.50

Price Performance

Historical Comparison
TVTX
MC

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About MC Moelis & Company

Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.

Share on Social Networks: